Medtronic announced the formation of Medtronic CardioVascular, a new global business combining the firm's vascular and cardiac surgery businesses.
Medtronic CardioVascular will have combined revenues of approximately $1.9 billion, the company said, and will consist of four major product divisions:
Coronary and peripheral -- minimally invasive catheter and stent-based technologies for the treatment of atherosclerosis;
Endovascular innovations -- stent grafts for the treatment of aortic abdominal and thoracic aneurysms;
Structural heart disease -- products for the treatment of heart valve disease and atrial fibrillation; and
Revascularization and surgical therapies -- open heart and coronary bypass grafting surgical products.